导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.86% | 2771/4773 |
| 近一周 | -2.99% | 3519/5462 |
| 近一月 | -7.49% | 3841/5421 |
| 近一季 | 12.75% | 103/5209 |
| 近半年 | 1.56% | 1037/4920 |
| 近一年 | -16.57% | 3802/4366 |
| 近两年 | 22.57% | 2590/2954 |
| 近三年 | -8.56% | 2018/2253 |
| 成立以来 | 19.94% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.77% 2901/4961 |
-3.60% 3465/5312 |
- - |
- - |
| 2025 | 9.58% 2861/4813 |
3.93% 1017/3635 |
2.05% 1925/4076 |
20.84% 1911/4524 |
-14.49% 4344/4813 |
| 2024 | -17.80% 2516/3463 |
-14.19% 2509/2808 |
-10.23% 2430/3014 |
18.90% 913/3129 |
-10.25% 2976/3463 |
| 2023 | -11.36% 1395/2656 |
-2.49% 1998/2280 |
-11.08% 2140/2385 |
1.73% 285/2515 |
0.49% 144/2655 |
| 2022 | -26.81% 1436/2207 |
-10.60% 405/1919 |
-4.99% 1862/2016 |
-19.71% 1806/2113 |
7.31% 319/2208 |
| 2021 | -14.06% 1142/1822 |
-3.90% 833/1255 |
14.27% 261/1330 |
-14.06% 1361/1466 |
-8.93% 1591/1822 |
| 2020 | 86.02% 29/1250 |
16.02% 2/1028 |
38.57% 8/1067 |
7.27% 793/1164 |
7.87% 692/1184 |
| 2019 | 53.15% 85/1092 |
34.59% 108/754 |
-2.75% 361/804 |
11.25% 37/850 |
5.18% 740/918 |
| 2018 | -24.70% 328/834 |
- - |
- - |
- - |
-19.85% 665/691 |
| 2017 | 14.94% 250/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 汇添富中证生物科技指数(LOF)A VS. 长安沪深300非周期A(740101) |